Current Research

Check out the studies at Yale that are currently recruiting!

Less than 8 years old

Type 1 diabetes and the brain in children: Metabolic interventions

(HIC#1411014935)

This study is designed to look at how diabetes impacts the development of the brain, memory and thinking in young children. 

Age: 7-13 years old, both children with diabetes and without diabetes

More information: Direcnet Study

Contact: Amy Steffen at amy.steffen@yale.edu or 203-737-8852

Age 8- 17 years

These are studies for children age 8 to 17 years old.

Type 1 diabetes and the brain in children: Metabolic interventions

(HIC#1411014935)

This study is designed to look at how diabetes impacts the development of the brain, memory and thinking in young children. 

Age: 7-13 years old, both children with diabetes and without diabetes

More information: Direcnet Study

Contact: Amy Steffen at amy.steffen@yale.edu or 203-737-8852


Residual Insulin Study

(HIC# 0903004911)

The purpose of this study is to determine if participants with long-standing diabetes (more than two years) continue to produce some insulin. 

Ages: 15-40 years old 

Contact: Linda Rink at linda.rink@yale.edu or 203-737-4510

More Information: Residual Insulin Study

Adult age 18+

Artificial Pancreas Liraglutide Study

(HIC#1211011156)

This study is designed to look at how well young adults' blood sugar can be controlled with Artificial Pancreas Liraglutide Study

(HIC#1211011156)

This study is designed to look at how well young adults' blood sugar can be controlled with a "closed loop artificial pancreas" along with the drug Liraglutide (Victoza)

Age: 18-40 years old

More InformationLiraglutide Study

Contact: Lori Carria at Lori.Carria@yale.edu or 203-737-3595 


Residual Insulin Study

(HIC#0903004911)

The purpose of this study is to determine if participants with long-standing diabetes (more than 2 years) continue to produce some insulin.

Age: 15-40 years old

More Information:

Residual Insulin Study

Contact: Linda Rink at 203-737-4510 or linda.rink@yale.edu

a "closed loop artificial pancreas" along with the drug Liraglutide (Victoza)

Age : 18-40 years old

More InformationLiraglutide Study

Contact: Lori Carria at Lori.Carria@yale.edu or 203-737-3595 


Residual Insulin Study

(HIC#0903004911)

The purpose of this study is to determine if participants with long-standing diabetes (more than 2 years) continue to produce some insulin.

Age:  15-40 years old

More Information:

Residual Insulin Study

Contact: Linda Rink at 203-737-4510 or linda.rink@yale.edu

New Diagnosis

These study are recruiting for patients who have a recent diagnosis of type 1 diabetes.

A Phase I Safety Trial of CD4+CD127lo/-CD25+ Polyclonal Treg Adoptive Immunotherapy for the Treatment of Type 1 Diabetes 

THIS TREATMENT PROTOCOL IS NOW OPEN AT YALE

This is an open-label dose escalation study in which cohorts of subjects with T1DM will receive increasing doses of a single infusion of ex vivo selected and expanded autologous regulatory T cells (T-regs; defined as CD4+CD127lo/-CD25+ cells).

Ages: 18 and 35 years of age

More informationPhase 1 Safety Trial of CD4

Contact: Linda.Rink@yale.edu

Prevention and Family

These studies target people with relatives with Type 1 Diabetes or people who have been identified as being at risk for Type 1 Diabetes.


The Natural History Study of the Development of Type 1 Diabetes: Pathway to Prevention FOR FAMILY MEMBERS ONLY

(HIC # 0608001761)

The goal of this study is to learn more about how type 1 diabetes develops in "at-risk" individuals and is the first step in determining eligibility for prevention trials.

Ages: If you are 1-45 years of age AND have a brother, sister, child or parent with type 1 diabetes OR you are 1-20 years of age AND have a cousin, aunt, uncle, niece, nephew, half-sibling or grandparent with type 1 diabetes.

More information: Natural History Study

Contact: Laurie Feldman (203) 737-2760 or laurie.feldman@yale.edu


Oral Insulin for Prevention of T1DM in Family Members at Risk

(HIC# 0710003160)

The goal of this study is to see if oral insulin help to delay or prevent type 1 diabetes in family members identified to be at increased risk for the disease. Participants in this study were screened in the Natural History Study.

Ages: 3-45 years old

More information: Oral Insulin for Prevention of T1DM Study

Contact: Laurie Feldman (203) 737-2760 or laurie.feldman@yale.edu


TrialNet Anti CD3 (Teplizumab) for the Prevention

(HIC#1006007008)

TrialNet investigators are testing a medication, called Te plizumab, to see if this treatment will delay or prevent the onset of type 1 diabetes in family members identified to be at high risk for the disease. Participants in this study were screened in the Natural History Study.

Ages: 8-45 years old

More information: TrialNet Anti CD3 Study

Contact: Laurie Feldman (203) 737-2760 or laurie.feldman@yale.edu


CTLA4-Ig (Abatacept) for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At-Risk for TID

(HIC# 1211011152)

TrialNet investigators are testing a medication, called Abatacept, to see if this treatment will delay or prevent the onset of type 1 diabetes in family members identified to be at risk for the disease. Participants in this study were screened in the Natural History/Pathway to Prevention Study.

Ages: at least 6 years old

More information: Abatacept

Contact: Laurie Feldman (203) 737-2760 or laurie.feldman@yale.edu